nodes	percent_of_prediction	percent_of_DWPC	metapath
Vincristine—NR0B1—Dexamethasone—psoriasis	0.121	0.154	CbGbCtD
Vincristine—ABCC10—Cyclosporine—psoriasis	0.0672	0.0859	CbGbCtD
Vincristine—ABCC3—Cyclosporine—psoriasis	0.0422	0.054	CbGbCtD
Vincristine—ABCB11—Cyclosporine—psoriasis	0.0365	0.0467	CbGbCtD
Vincristine—ABCC10—Methotrexate—psoriasis	0.0355	0.0455	CbGbCtD
Vincristine—CYP3A5—Beclomethasone—psoriasis	0.0319	0.0407	CbGbCtD
Vincristine—ABCC1—Cyclosporine—psoriasis	0.0259	0.0332	CbGbCtD
Vincristine—ABCC2—Mycophenolate mofetil—psoriasis	0.0253	0.0324	CbGbCtD
Vincristine—ABCB11—Dexamethasone—psoriasis	0.024	0.0307	CbGbCtD
Vincristine—ABCG2—Mycophenolate mofetil—psoriasis	0.0229	0.0293	CbGbCtD
Vincristine—ABCC3—Methotrexate—psoriasis	0.0224	0.0286	CbGbCtD
Vincristine—ABCC2—Cyclosporine—psoriasis	0.0192	0.0245	CbGbCtD
Vincristine—ABCG2—Hydrocortisone—psoriasis	0.0184	0.0235	CbGbCtD
Vincristine—ABCG2—Cyclosporine—psoriasis	0.0174	0.0222	CbGbCtD
Vincristine—ABCC1—Methotrexate—psoriasis	0.0137	0.0175	CbGbCtD
Vincristine—CYP3A7—Hydrocortisone—psoriasis	0.0136	0.0174	CbGbCtD
Vincristine—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0136	0.0174	CbGbCtD
Vincristine—CYP3A7—Cyclosporine—psoriasis	0.0128	0.0164	CbGbCtD
Vincristine—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0128	0.0164	CbGbCtD
Vincristine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0127	0.0162	CbGbCtD
Vincristine—ABCC2—Dexamethasone—psoriasis	0.0126	0.0162	CbGbCtD
Vincristine—ABCG2—Dexamethasone—psoriasis	0.0114	0.0146	CbGbCtD
Vincristine—CYP3A4—Calcitriol—psoriasis	0.0111	0.0142	CbGbCtD
Vincristine—CYP3A5—Hydrocortisone—psoriasis	0.0102	0.013	CbGbCtD
Vincristine—ABCC2—Methotrexate—psoriasis	0.0102	0.013	CbGbCtD
Vincristine—CYP3A5—Cyclosporine—psoriasis	0.00962	0.0123	CbGbCtD
Vincristine—ABCG2—Methotrexate—psoriasis	0.00918	0.0117	CbGbCtD
Vincristine—CYP3A4—Methoxsalen—psoriasis	0.00861	0.011	CbGbCtD
Vincristine—CYP3A7—Dexamethasone—psoriasis	0.00844	0.0108	CbGbCtD
Vincristine—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.00844	0.0108	CbGbCtD
Vincristine—ABCB1—Mycophenolate mofetil—psoriasis	0.00826	0.0106	CbGbCtD
Vincristine—ABCB1—Betamethasone—psoriasis	0.00708	0.00906	CbGbCtD
Vincristine—ABCB1—Prednisolone—psoriasis	0.00699	0.00894	CbGbCtD
Vincristine—ABCB1—Hydrocortisone—psoriasis	0.00663	0.00847	CbGbCtD
Vincristine—ABCB1—Prednisone—psoriasis	0.0066	0.00844	CbGbCtD
Vincristine—CYP3A5—Dexamethasone—psoriasis	0.00633	0.0081	CbGbCtD
Vincristine—ABCB1—Cyclosporine—psoriasis	0.00626	0.008	CbGbCtD
Vincristine—CYP3A4—Cholecalciferol—psoriasis	0.00571	0.0073	CbGbCtD
Vincristine—CYP3A4—Triamcinolone—psoriasis	0.00495	0.00633	CbGbCtD
Vincristine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00495	0.00633	CbGbCtD
Vincristine—CYP3A4—Betamethasone—psoriasis	0.00424	0.00543	CbGbCtD
Vincristine—CYP3A4—Prednisolone—psoriasis	0.00419	0.00535	CbGbCtD
Vincristine—ABCB1—Dexamethasone—psoriasis	0.00412	0.00527	CbGbCtD
Vincristine—CYP3A4—Hydrocortisone—psoriasis	0.00397	0.00508	CbGbCtD
Vincristine—CYP3A4—Prednisone—psoriasis	0.00396	0.00506	CbGbCtD
Vincristine—CYP3A4—Cyclosporine—psoriasis	0.00375	0.00479	CbGbCtD
Vincristine—Vinblastine—JUN—psoriasis	0.00363	1	CrCbGaD
Vincristine—ABCB1—Methotrexate—psoriasis	0.00331	0.00423	CbGbCtD
Vincristine—CYP3A4—Dexamethasone—psoriasis	0.00247	0.00316	CbGbCtD
Vincristine—TUBB6—Vitamin A—Acitretin—psoriasis	0.00138	0.323	CbGdCrCtD
Vincristine—TUBB6—Isotretinoin—Acitretin—psoriasis	0.000962	0.226	CbGdCrCtD
Vincristine—TUBB6—Alitretinoin—Acitretin—psoriasis	0.000962	0.226	CbGdCrCtD
Vincristine—TUBB6—Tretinoin—Acitretin—psoriasis	0.000962	0.226	CbGdCrCtD
Vincristine—ABCG2—Iron uptake and transport—CP—psoriasis	0.000241	0.0101	CbGpPWpGaD
Vincristine—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00024	0.0101	CbGpPWpGaD
Vincristine—TUBB4A—Orphan transporters—CARM1—psoriasis	0.000221	0.00929	CbGpPWpGaD
Vincristine—NR0B1—Regulation of Androgen receptor activity—JUN—psoriasis	0.000215	0.00906	CbGpPWpGaD
Vincristine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00021	0.00882	CbGpPWpGaD
Vincristine—TUBB4B—Orphan transporters—CARM1—psoriasis	0.000202	0.0085	CbGpPWpGaD
Vincristine—NR0B1—Gene Expression—TARS—psoriasis	0.000199	0.00836	CbGpPWpGaD
Vincristine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000198	0.00835	CbGpPWpGaD
Vincristine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000191	0.00802	CbGpPWpGaD
Vincristine—NR0B1—Validated nuclear estrogen receptor alpha network—JUN—psoriasis	0.000185	0.00779	CbGpPWpGaD
Vincristine—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000175	0.00736	CbGpPWpGaD
Vincristine—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000171	0.0072	CbGpPWpGaD
Vincristine—RALBP1—EGF/EGFR Signaling Pathway—PCNA—psoriasis	0.000168	0.00707	CbGpPWpGaD
Vincristine—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000168	0.00705	CbGpPWpGaD
Vincristine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000156	0.00657	CbGpPWpGaD
Vincristine—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000154	0.00648	CbGpPWpGaD
Vincristine—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000152	0.00639	CbGpPWpGaD
Vincristine—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000133	0.00559	CbGpPWpGaD
Vincristine—Vertigo—Triamcinolone—psoriasis	0.000131	0.000701	CcSEcCtD
Vincristine—NR0B1—Generic Transcription Pathway—CARM1—psoriasis	0.00013	0.00546	CbGpPWpGaD
Vincristine—ABCC1—S1P1 pathway—VEGFA—psoriasis	0.00013	0.00546	CbGpPWpGaD
Vincristine—Connective tissue disorder—Prednisone—psoriasis	0.00013	0.000696	CcSEcCtD
Vincristine—Hypotension—Mycophenolate mofetil—psoriasis	0.000129	0.000693	CcSEcCtD
Vincristine—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000129	0.000693	CcSEcCtD
Vincristine—Oedema—Prednisolone—psoriasis	0.000129	0.000692	CcSEcCtD
Vincristine—Anaphylactic shock—Prednisolone—psoriasis	0.000129	0.000692	CcSEcCtD
Vincristine—Neutropenia—Methotrexate—psoriasis	0.000129	0.000691	CcSEcCtD
Vincristine—Dysuria—Methotrexate—psoriasis	0.000129	0.000691	CcSEcCtD
Vincristine—Insomnia—Cyclosporine—psoriasis	0.000128	0.000688	CcSEcCtD
Vincristine—Paraesthesia—Cyclosporine—psoriasis	0.000127	0.000683	CcSEcCtD
Vincristine—Erectile dysfunction—Methotrexate—psoriasis	0.000127	0.000681	CcSEcCtD
Vincristine—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000126	0.000676	CcSEcCtD
Vincristine—Anaphylactic shock—Hydrocortisone—psoriasis	0.000126	0.000676	CcSEcCtD
Vincristine—Oedema—Hydrocortisone—psoriasis	0.000126	0.000676	CcSEcCtD
Vincristine—Convulsion—Triamcinolone—psoriasis	0.000126	0.000676	CcSEcCtD
Vincristine—Photosensitivity reaction—Methotrexate—psoriasis	0.000126	0.000675	CcSEcCtD
Vincristine—Asthenia—Mycophenolic acid—psoriasis	0.000126	0.000675	CcSEcCtD
Vincristine—ABCC3—NRF2 pathway—TGFA—psoriasis	0.000125	0.00528	CbGpPWpGaD
Vincristine—Hypertension—Triamcinolone—psoriasis	0.000125	0.000673	CcSEcCtD
Vincristine—Infection—Hydrocortisone—psoriasis	0.000125	0.000672	CcSEcCtD
Vincristine—Insomnia—Mycophenolate mofetil—psoriasis	0.000125	0.000671	CcSEcCtD
Vincristine—Hyperhidrosis—Prednisolone—psoriasis	0.000125	0.000669	CcSEcCtD
Vincristine—Nausea—Hydroxyurea—psoriasis	0.000124	0.000667	CcSEcCtD
Vincristine—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000124	0.000666	CcSEcCtD
Vincristine—Myalgia—Triamcinolone—psoriasis	0.000124	0.000664	CcSEcCtD
Vincristine—Nervous system disorder—Hydrocortisone—psoriasis	0.000123	0.000663	CcSEcCtD
Vincristine—Pneumonia—Methotrexate—psoriasis	0.000123	0.000663	CcSEcCtD
Vincristine—Decreased appetite—Cyclosporine—psoriasis	0.000123	0.000661	CcSEcCtD
Vincristine—Depression—Methotrexate—psoriasis	0.000122	0.000657	CcSEcCtD
Vincristine—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000122	0.000657	CcSEcCtD
Vincristine—Fatigue—Cyclosporine—psoriasis	0.000122	0.000656	CcSEcCtD
Vincristine—Hyperhidrosis—Hydrocortisone—psoriasis	0.000122	0.000653	CcSEcCtD
Vincristine—TUBA4A—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000121	0.0051	CbGpPWpGaD
Vincristine—Constipation—Cyclosporine—psoriasis	0.000121	0.00065	CcSEcCtD
Vincristine—Pain—Cyclosporine—psoriasis	0.000121	0.00065	CcSEcCtD
Vincristine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00012	0.00506	CbGpPWpGaD
Vincristine—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00012	0.000645	CcSEcCtD
Vincristine—Anorexia—Hydrocortisone—psoriasis	0.00012	0.000644	CcSEcCtD
Vincristine—Diarrhoea—Mycophenolic acid—psoriasis	0.00012	0.000643	CcSEcCtD
Vincristine—Stomatitis—Methotrexate—psoriasis	0.00012	0.000642	CcSEcCtD
Vincristine—Angiopathy—Prednisone—psoriasis	0.00012	0.000642	CcSEcCtD
Vincristine—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000119	0.000641	CcSEcCtD
Vincristine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000119	0.00499	CbGpPWpGaD
Vincristine—Anaphylactic shock—Triamcinolone—psoriasis	0.000119	0.000636	CcSEcCtD
Vincristine—Oedema—Triamcinolone—psoriasis	0.000119	0.000636	CcSEcCtD
Vincristine—Vertigo—Betamethasone—psoriasis	0.000118	0.000636	CcSEcCtD
Vincristine—Vertigo—Dexamethasone—psoriasis	0.000118	0.000636	CcSEcCtD
Vincristine—Constipation—Mycophenolate mofetil—psoriasis	0.000118	0.000634	CcSEcCtD
Vincristine—Pain—Mycophenolate mofetil—psoriasis	0.000118	0.000634	CcSEcCtD
Vincristine—Infection—Triamcinolone—psoriasis	0.000118	0.000632	CcSEcCtD
Vincristine—Sweating—Methotrexate—psoriasis	0.000118	0.000632	CcSEcCtD
Vincristine—Hypotension—Hydrocortisone—psoriasis	0.000118	0.000632	CcSEcCtD
Vincristine—Insomnia—Prednisolone—psoriasis	0.000117	0.000626	CcSEcCtD
Vincristine—Alopecia—Prednisone—psoriasis	0.000117	0.000626	CcSEcCtD
Vincristine—Gastrointestinal pain—Cyclosporine—psoriasis	0.000116	0.000622	CcSEcCtD
Vincristine—Dizziness—Mycophenolic acid—psoriasis	0.000116	0.000622	CcSEcCtD
Vincristine—Paraesthesia—Prednisolone—psoriasis	0.000116	0.000621	CcSEcCtD
Vincristine—Mental disorder—Prednisone—psoriasis	0.000116	0.00062	CcSEcCtD
Vincristine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000115	0.000616	CcSEcCtD
Vincristine—Hyperhidrosis—Triamcinolone—psoriasis	0.000115	0.000615	CcSEcCtD
Vincristine—Convulsion—Dexamethasone—psoriasis	0.000114	0.000613	CcSEcCtD
Vincristine—Convulsion—Betamethasone—psoriasis	0.000114	0.000613	CcSEcCtD
Vincristine—Insomnia—Hydrocortisone—psoriasis	0.000114	0.000611	CcSEcCtD
Vincristine—Hypertension—Betamethasone—psoriasis	0.000114	0.000611	CcSEcCtD
Vincristine—Hypertension—Dexamethasone—psoriasis	0.000114	0.000611	CcSEcCtD
Vincristine—Paraesthesia—Hydrocortisone—psoriasis	0.000113	0.000607	CcSEcCtD
Vincristine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000113	0.000607	CcSEcCtD
Vincristine—Myalgia—Dexamethasone—psoriasis	0.000112	0.000602	CcSEcCtD
Vincristine—Myalgia—Betamethasone—psoriasis	0.000112	0.000602	CcSEcCtD
Vincristine—Abdominal pain—Cyclosporine—psoriasis	0.000112	0.000601	CcSEcCtD
Vincristine—Body temperature increased—Cyclosporine—psoriasis	0.000112	0.000601	CcSEcCtD
Vincristine—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000111	0.00469	CbGpPWpGaD
Vincristine—Vomiting—Mycophenolic acid—psoriasis	0.000111	0.000598	CcSEcCtD
Vincristine—Rash—Mycophenolic acid—psoriasis	0.00011	0.000593	CcSEcCtD
Vincristine—Dermatitis—Mycophenolic acid—psoriasis	0.00011	0.000592	CcSEcCtD
Vincristine—Pain—Prednisolone—psoriasis	0.00011	0.000592	CcSEcCtD
Vincristine—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.00011	0.00462	CbGpPWpGaD
Vincristine—Headache—Mycophenolic acid—psoriasis	0.00011	0.000589	CcSEcCtD
Vincristine—Decreased appetite—Hydrocortisone—psoriasis	0.000109	0.000588	CcSEcCtD
Vincristine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000109	0.000587	CcSEcCtD
Vincristine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000109	0.000587	CcSEcCtD
Vincristine—Urinary tract disorder—Methotrexate—psoriasis	0.000109	0.000584	CcSEcCtD
Vincristine—ABCC10—Transmembrane transport of small molecules—CP—psoriasis	0.000109	0.00458	CbGpPWpGaD
Vincristine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000109	0.000584	CcSEcCtD
Vincristine—Fatigue—Hydrocortisone—psoriasis	0.000109	0.000583	CcSEcCtD
Vincristine—TUBA4A—Cell Cycle—PTTG1—psoriasis	0.000108	0.00456	CbGpPWpGaD
Vincristine—Urethral disorder—Methotrexate—psoriasis	0.000108	0.00058	CcSEcCtD
Vincristine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000108	0.00058	CcSEcCtD
Vincristine—Pain—Hydrocortisone—psoriasis	0.000108	0.000578	CcSEcCtD
Vincristine—Anaphylactic shock—Betamethasone—psoriasis	0.000108	0.000578	CcSEcCtD
Vincristine—Oedema—Betamethasone—psoriasis	0.000108	0.000578	CcSEcCtD
Vincristine—Oedema—Dexamethasone—psoriasis	0.000108	0.000578	CcSEcCtD
Vincristine—Anaphylactic shock—Dexamethasone—psoriasis	0.000108	0.000578	CcSEcCtD
Vincristine—TUBB2A—Signaling events mediated by HDAC Class III—TP53—psoriasis	0.000107	0.00452	CbGpPWpGaD
Vincristine—Insomnia—Triamcinolone—psoriasis	0.000107	0.000576	CcSEcCtD
Vincristine—Infection—Dexamethasone—psoriasis	0.000107	0.000574	CcSEcCtD
Vincristine—Infection—Betamethasone—psoriasis	0.000107	0.000574	CcSEcCtD
Vincristine—Paraesthesia—Triamcinolone—psoriasis	0.000106	0.000572	CcSEcCtD
Vincristine—Anaemia—Prednisone—psoriasis	0.000106	0.00057	CcSEcCtD
Vincristine—Nervous system disorder—Dexamethasone—psoriasis	0.000105	0.000566	CcSEcCtD
Vincristine—Nervous system disorder—Betamethasone—psoriasis	0.000105	0.000566	CcSEcCtD
Vincristine—Agitation—Prednisone—psoriasis	0.000105	0.000566	CcSEcCtD
Vincristine—Thrombocytopenia—Betamethasone—psoriasis	0.000105	0.000565	CcSEcCtD
Vincristine—Thrombocytopenia—Dexamethasone—psoriasis	0.000105	0.000565	CcSEcCtD
Vincristine—Hypersensitivity—Cyclosporine—psoriasis	0.000104	0.00056	CcSEcCtD
Vincristine—Nausea—Mycophenolic acid—psoriasis	0.000104	0.000558	CcSEcCtD
Vincristine—Hyperhidrosis—Betamethasone—psoriasis	0.000104	0.000558	CcSEcCtD
Vincristine—Hyperhidrosis—Dexamethasone—psoriasis	0.000104	0.000558	CcSEcCtD
Vincristine—ABCC10—Transmembrane transport of small molecules—CARM1—psoriasis	0.000104	0.00437	CbGpPWpGaD
Vincristine—TUBB—Cell Cycle, Mitotic—PTTG1—psoriasis	0.000103	0.00434	CbGpPWpGaD
Vincristine—Vertigo—Prednisone—psoriasis	0.000103	0.000554	CcSEcCtD
Vincristine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000103	0.000553	CcSEcCtD
Vincristine—Anorexia—Betamethasone—psoriasis	0.000103	0.000551	CcSEcCtD
Vincristine—Anorexia—Dexamethasone—psoriasis	0.000103	0.000551	CcSEcCtD
Vincristine—Cardiac disorder—Methotrexate—psoriasis	0.000102	0.000549	CcSEcCtD
Vincristine—Fatigue—Triamcinolone—psoriasis	0.000102	0.000549	CcSEcCtD
Vincristine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000102	0.000547	CcSEcCtD
Vincristine—Asthenia—Cyclosporine—psoriasis	0.000102	0.000546	CcSEcCtD
Vincristine—Pain—Triamcinolone—psoriasis	0.000101	0.000544	CcSEcCtD
Vincristine—Hypotension—Dexamethasone—psoriasis	0.000101	0.00054	CcSEcCtD
Vincristine—Hypotension—Betamethasone—psoriasis	0.000101	0.00054	CcSEcCtD
Vincristine—Angiopathy—Methotrexate—psoriasis	0.0001	0.000537	CcSEcCtD
Vincristine—TUBA4A—Platelet degranulation—VEGFA—psoriasis	9.97e-05	0.0042	CbGpPWpGaD
Vincristine—Body temperature increased—Hydrocortisone—psoriasis	9.95e-05	0.000534	CcSEcCtD
Vincristine—Abdominal pain—Hydrocortisone—psoriasis	9.95e-05	0.000534	CcSEcCtD
Vincristine—ABCC2—NRF2 pathway—TGFA—psoriasis	9.95e-05	0.00419	CbGpPWpGaD
Vincristine—Convulsion—Prednisone—psoriasis	9.94e-05	0.000534	CcSEcCtD
Vincristine—Mediastinal disorder—Methotrexate—psoriasis	9.93e-05	0.000533	CcSEcCtD
Vincristine—Asthenia—Mycophenolate mofetil—psoriasis	9.91e-05	0.000532	CcSEcCtD
Vincristine—Hypertension—Prednisone—psoriasis	9.91e-05	0.000532	CcSEcCtD
Vincristine—Musculoskeletal discomfort—Dexamethasone—psoriasis	9.8e-05	0.000526	CcSEcCtD
Vincristine—Musculoskeletal discomfort—Betamethasone—psoriasis	9.8e-05	0.000526	CcSEcCtD
Vincristine—RALBP1—Signaling Pathways—HCAR2—psoriasis	9.79e-05	0.00412	CbGpPWpGaD
Vincristine—Myalgia—Prednisone—psoriasis	9.77e-05	0.000525	CcSEcCtD
Vincristine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.75e-05	0.0041	CbGpPWpGaD
Vincristine—Alopecia—Methotrexate—psoriasis	9.74e-05	0.000523	CcSEcCtD
Vincristine—Insomnia—Dexamethasone—psoriasis	9.73e-05	0.000522	CcSEcCtD
Vincristine—Insomnia—Betamethasone—psoriasis	9.73e-05	0.000522	CcSEcCtD
Vincristine—Diarrhoea—Cyclosporine—psoriasis	9.69e-05	0.00052	CcSEcCtD
Vincristine—Paraesthesia—Dexamethasone—psoriasis	9.66e-05	0.000519	CcSEcCtD
Vincristine—Paraesthesia—Betamethasone—psoriasis	9.66e-05	0.000519	CcSEcCtD
Vincristine—Mental disorder—Methotrexate—psoriasis	9.65e-05	0.000518	CcSEcCtD
Vincristine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	9.61e-05	0.00405	CbGpPWpGaD
Vincristine—TUBA4A—Hemostasis—ITGAL—psoriasis	9.59e-05	0.00404	CbGpPWpGaD
Vincristine—TUBA4A—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	9.5e-05	0.004	CbGpPWpGaD
Vincristine—Hypersensitivity—Prednisolone—psoriasis	9.5e-05	0.00051	CcSEcCtD
Vincristine—Diarrhoea—Mycophenolate mofetil—psoriasis	9.46e-05	0.000508	CcSEcCtD
Vincristine—Body temperature increased—Triamcinolone—psoriasis	9.37e-05	0.000503	CcSEcCtD
Vincristine—Dizziness—Cyclosporine—psoriasis	9.37e-05	0.000503	CcSEcCtD
Vincristine—Oedema—Prednisone—psoriasis	9.37e-05	0.000503	CcSEcCtD
Vincristine—Anaphylactic shock—Prednisone—psoriasis	9.37e-05	0.000503	CcSEcCtD
Vincristine—RALBP1—EGF/EGFR Signaling Pathway—JUN—psoriasis	9.36e-05	0.00394	CbGpPWpGaD
Vincristine—Decreased appetite—Dexamethasone—psoriasis	9.35e-05	0.000502	CcSEcCtD
Vincristine—Decreased appetite—Betamethasone—psoriasis	9.35e-05	0.000502	CcSEcCtD
Vincristine—Infection—Prednisone—psoriasis	9.31e-05	0.0005	CcSEcCtD
Vincristine—Gastrointestinal disorder—Betamethasone—psoriasis	9.29e-05	0.000499	CcSEcCtD
Vincristine—Gastrointestinal disorder—Dexamethasone—psoriasis	9.29e-05	0.000499	CcSEcCtD
Vincristine—Back pain—Methotrexate—psoriasis	9.28e-05	0.000498	CcSEcCtD
Vincristine—Hypersensitivity—Hydrocortisone—psoriasis	9.28e-05	0.000498	CcSEcCtD
Vincristine—Fatigue—Dexamethasone—psoriasis	9.27e-05	0.000498	CcSEcCtD
Vincristine—Fatigue—Betamethasone—psoriasis	9.27e-05	0.000498	CcSEcCtD
Vincristine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	9.26e-05	0.00389	CbGpPWpGaD
Vincristine—TUBB—Cell Cycle—PTTG1—psoriasis	9.22e-05	0.00388	CbGpPWpGaD
Vincristine—Pain—Betamethasone—psoriasis	9.2e-05	0.000494	CcSEcCtD
Vincristine—Pain—Dexamethasone—psoriasis	9.2e-05	0.000494	CcSEcCtD
Vincristine—Nervous system disorder—Prednisone—psoriasis	9.19e-05	0.000493	CcSEcCtD
Vincristine—Dizziness—Mycophenolate mofetil—psoriasis	9.14e-05	0.000491	CcSEcCtD
Vincristine—Hyperhidrosis—Prednisone—psoriasis	9.06e-05	0.000486	CcSEcCtD
Vincristine—Asthenia—Hydrocortisone—psoriasis	9.03e-05	0.000485	CcSEcCtD
Vincristine—SLC22A3—SLC-mediated transmembrane transport—CP—psoriasis	9.02e-05	0.0038	CbGpPWpGaD
Vincristine—Vomiting—Cyclosporine—psoriasis	9.01e-05	0.000484	CcSEcCtD
Vincristine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.96e-05	0.00377	CbGpPWpGaD
Vincristine—Rash—Cyclosporine—psoriasis	8.93e-05	0.00048	CcSEcCtD
Vincristine—Anorexia—Prednisone—psoriasis	8.93e-05	0.000479	CcSEcCtD
Vincristine—Dermatitis—Cyclosporine—psoriasis	8.92e-05	0.000479	CcSEcCtD
Vincristine—Headache—Cyclosporine—psoriasis	8.87e-05	0.000476	CcSEcCtD
Vincristine—Anaemia—Methotrexate—psoriasis	8.87e-05	0.000476	CcSEcCtD
Vincristine—Gastrointestinal pain—Dexamethasone—psoriasis	8.8e-05	0.000472	CcSEcCtD
Vincristine—Gastrointestinal pain—Betamethasone—psoriasis	8.8e-05	0.000472	CcSEcCtD
Vincristine—Vomiting—Mycophenolate mofetil—psoriasis	8.79e-05	0.000472	CcSEcCtD
Vincristine—Hypersensitivity—Triamcinolone—psoriasis	8.73e-05	0.000469	CcSEcCtD
Vincristine—Rash—Mycophenolate mofetil—psoriasis	8.71e-05	0.000468	CcSEcCtD
Vincristine—Dermatitis—Mycophenolate mofetil—psoriasis	8.71e-05	0.000467	CcSEcCtD
Vincristine—Headache—Mycophenolate mofetil—psoriasis	8.66e-05	0.000465	CcSEcCtD
Vincristine—Vertigo—Methotrexate—psoriasis	8.62e-05	0.000463	CcSEcCtD
Vincristine—Diarrhoea—Hydrocortisone—psoriasis	8.61e-05	0.000463	CcSEcCtD
Vincristine—Leukopenia—Methotrexate—psoriasis	8.59e-05	0.000461	CcSEcCtD
Vincristine—TUBA4A—Metabolism of proteins—REN—psoriasis	8.57e-05	0.00361	CbGpPWpGaD
Vincristine—TUBB4A—Cell Cycle, Mitotic—PTTG1—psoriasis	8.55e-05	0.0036	CbGpPWpGaD
Vincristine—Musculoskeletal discomfort—Prednisone—psoriasis	8.53e-05	0.000458	CcSEcCtD
Vincristine—Dizziness—Prednisolone—psoriasis	8.52e-05	0.000458	CcSEcCtD
Vincristine—Asthenia—Triamcinolone—psoriasis	8.51e-05	0.000457	CcSEcCtD
Vincristine—Body temperature increased—Betamethasone—psoriasis	8.5e-05	0.000457	CcSEcCtD
Vincristine—Abdominal pain—Betamethasone—psoriasis	8.5e-05	0.000457	CcSEcCtD
Vincristine—Body temperature increased—Dexamethasone—psoriasis	8.5e-05	0.000457	CcSEcCtD
Vincristine—Abdominal pain—Dexamethasone—psoriasis	8.5e-05	0.000457	CcSEcCtD
Vincristine—RALBP1—Signaling Pathways—TAGAP—psoriasis	8.49e-05	0.00357	CbGpPWpGaD
Vincristine—Insomnia—Prednisone—psoriasis	8.47e-05	0.000455	CcSEcCtD
Vincristine—Nausea—Cyclosporine—psoriasis	8.41e-05	0.000452	CcSEcCtD
Vincristine—Paraesthesia—Prednisone—psoriasis	8.41e-05	0.000452	CcSEcCtD
Vincristine—Dizziness—Hydrocortisone—psoriasis	8.33e-05	0.000447	CcSEcCtD
Vincristine—Convulsion—Methotrexate—psoriasis	8.31e-05	0.000446	CcSEcCtD
Vincristine—Nausea—Mycophenolate mofetil—psoriasis	8.21e-05	0.000441	CcSEcCtD
Vincristine—Myalgia—Methotrexate—psoriasis	8.17e-05	0.000438	CcSEcCtD
Vincristine—Decreased appetite—Prednisone—psoriasis	8.14e-05	0.000437	CcSEcCtD
Vincristine—Rash—Prednisolone—psoriasis	8.13e-05	0.000436	CcSEcCtD
Vincristine—Dermatitis—Prednisolone—psoriasis	8.12e-05	0.000436	CcSEcCtD
Vincristine—RALBP1—EGF/EGFR Signaling Pathway—STAT3—psoriasis	8.1e-05	0.00341	CbGpPWpGaD
Vincristine—Fatigue—Prednisone—psoriasis	8.08e-05	0.000434	CcSEcCtD
Vincristine—Headache—Prednisolone—psoriasis	8.08e-05	0.000434	CcSEcCtD
Vincristine—ABCC3—Fluoropyrimidine Activity—TP53—psoriasis	8.04e-05	0.00338	CbGpPWpGaD
Vincristine—Constipation—Prednisone—psoriasis	8.01e-05	0.00043	CcSEcCtD
Vincristine—Vomiting—Hydrocortisone—psoriasis	8e-05	0.00043	CcSEcCtD
Vincristine—Rash—Hydrocortisone—psoriasis	7.94e-05	0.000426	CcSEcCtD
Vincristine—Dermatitis—Hydrocortisone—psoriasis	7.93e-05	0.000426	CcSEcCtD
Vincristine—Headache—Hydrocortisone—psoriasis	7.89e-05	0.000423	CcSEcCtD
Vincristine—Dizziness—Triamcinolone—psoriasis	7.84e-05	0.000421	CcSEcCtD
Vincristine—Anaphylactic shock—Methotrexate—psoriasis	7.83e-05	0.00042	CcSEcCtD
Vincristine—TUBB4B—Cell Cycle, Mitotic—PTTG1—psoriasis	7.82e-05	0.00329	CbGpPWpGaD
Vincristine—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	7.8e-05	0.00328	CbGpPWpGaD
Vincristine—Infection—Methotrexate—psoriasis	7.78e-05	0.000418	CcSEcCtD
Vincristine—NR0B1—Generic Transcription Pathway—VDR—psoriasis	7.75e-05	0.00326	CbGpPWpGaD
Vincristine—Asthenia—Dexamethasone—psoriasis	7.72e-05	0.000414	CcSEcCtD
Vincristine—Asthenia—Betamethasone—psoriasis	7.72e-05	0.000414	CcSEcCtD
Vincristine—Nervous system disorder—Methotrexate—psoriasis	7.68e-05	0.000412	CcSEcCtD
Vincristine—Thrombocytopenia—Methotrexate—psoriasis	7.66e-05	0.000412	CcSEcCtD
Vincristine—Gastrointestinal pain—Prednisone—psoriasis	7.66e-05	0.000411	CcSEcCtD
Vincristine—Nausea—Prednisolone—psoriasis	7.66e-05	0.000411	CcSEcCtD
Vincristine—TUBB4A—Cell Cycle—PTTG1—psoriasis	7.64e-05	0.00322	CbGpPWpGaD
Vincristine—Hyperhidrosis—Methotrexate—psoriasis	7.57e-05	0.000406	CcSEcCtD
Vincristine—Vomiting—Triamcinolone—psoriasis	7.54e-05	0.000405	CcSEcCtD
Vincristine—Nausea—Hydrocortisone—psoriasis	7.48e-05	0.000402	CcSEcCtD
Vincristine—Rash—Triamcinolone—psoriasis	7.47e-05	0.000401	CcSEcCtD
Vincristine—Dermatitis—Triamcinolone—psoriasis	7.47e-05	0.000401	CcSEcCtD
Vincristine—Anorexia—Methotrexate—psoriasis	7.46e-05	0.000401	CcSEcCtD
Vincristine—Headache—Triamcinolone—psoriasis	7.43e-05	0.000399	CcSEcCtD
Vincristine—Abdominal pain—Prednisone—psoriasis	7.41e-05	0.000398	CcSEcCtD
Vincristine—Body temperature increased—Prednisone—psoriasis	7.41e-05	0.000398	CcSEcCtD
Vincristine—Diarrhoea—Betamethasone—psoriasis	7.36e-05	0.000395	CcSEcCtD
Vincristine—Diarrhoea—Dexamethasone—psoriasis	7.36e-05	0.000395	CcSEcCtD
Vincristine—TUBB6—Metabolism of proteins—REN—psoriasis	7.35e-05	0.00309	CbGpPWpGaD
Vincristine—TUBB2B—Metabolism of proteins—REN—psoriasis	7.35e-05	0.00309	CbGpPWpGaD
Vincristine—Hypotension—Methotrexate—psoriasis	7.32e-05	0.000393	CcSEcCtD
Vincristine—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.27e-05	0.00306	CbGpPWpGaD
Vincristine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	7.16e-05	0.00301	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—HLA-C—psoriasis	7.14e-05	0.00301	CbGpPWpGaD
Vincristine—Musculoskeletal discomfort—Methotrexate—psoriasis	7.13e-05	0.000383	CcSEcCtD
Vincristine—Dizziness—Betamethasone—psoriasis	7.11e-05	0.000382	CcSEcCtD
Vincristine—Dizziness—Dexamethasone—psoriasis	7.11e-05	0.000382	CcSEcCtD
Vincristine—TUBB3—Metabolism of proteins—REN—psoriasis	7.1e-05	0.00299	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—IL13—psoriasis	7.1e-05	0.00299	CbGpPWpGaD
Vincristine—Insomnia—Methotrexate—psoriasis	7.08e-05	0.00038	CcSEcCtD
Vincristine—Nausea—Triamcinolone—psoriasis	7.04e-05	0.000378	CcSEcCtD
Vincristine—Paraesthesia—Methotrexate—psoriasis	7.03e-05	0.000377	CcSEcCtD
Vincristine—TUBB4B—Cell Cycle—PTTG1—psoriasis	6.99e-05	0.00294	CbGpPWpGaD
Vincristine—Hypersensitivity—Prednisone—psoriasis	6.9e-05	0.000371	CcSEcCtD
Vincristine—TUBB2B—Transmembrane transport of small molecules—CP—psoriasis	6.88e-05	0.0029	CbGpPWpGaD
Vincristine—TUBB6—Transmembrane transport of small molecules—CP—psoriasis	6.88e-05	0.0029	CbGpPWpGaD
Vincristine—TUBB2A—Metabolism of proteins—REN—psoriasis	6.88e-05	0.00289	CbGpPWpGaD
Vincristine—Vomiting—Betamethasone—psoriasis	6.84e-05	0.000367	CcSEcCtD
Vincristine—Vomiting—Dexamethasone—psoriasis	6.84e-05	0.000367	CcSEcCtD
Vincristine—Decreased appetite—Methotrexate—psoriasis	6.81e-05	0.000365	CcSEcCtD
Vincristine—Rash—Betamethasone—psoriasis	6.78e-05	0.000364	CcSEcCtD
Vincristine—Rash—Dexamethasone—psoriasis	6.78e-05	0.000364	CcSEcCtD
Vincristine—Dermatitis—Dexamethasone—psoriasis	6.78e-05	0.000364	CcSEcCtD
Vincristine—Dermatitis—Betamethasone—psoriasis	6.78e-05	0.000364	CcSEcCtD
Vincristine—Gastrointestinal disorder—Methotrexate—psoriasis	6.76e-05	0.000363	CcSEcCtD
Vincristine—Fatigue—Methotrexate—psoriasis	6.75e-05	0.000362	CcSEcCtD
Vincristine—Headache—Dexamethasone—psoriasis	6.74e-05	0.000362	CcSEcCtD
Vincristine—Headache—Betamethasone—psoriasis	6.74e-05	0.000362	CcSEcCtD
Vincristine—TUBB1—Metabolism of proteins—REN—psoriasis	6.73e-05	0.00283	CbGpPWpGaD
Vincristine—Asthenia—Prednisone—psoriasis	6.72e-05	0.000361	CcSEcCtD
Vincristine—Pain—Methotrexate—psoriasis	6.69e-05	0.000359	CcSEcCtD
Vincristine—TUBB3—Transmembrane transport of small molecules—CP—psoriasis	6.65e-05	0.0028	CbGpPWpGaD
Vincristine—TUBB2B—Transmembrane transport of small molecules—CARM1—psoriasis	6.56e-05	0.00276	CbGpPWpGaD
Vincristine—TUBB6—Transmembrane transport of small molecules—CARM1—psoriasis	6.56e-05	0.00276	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—IL17A—psoriasis	6.53e-05	0.00275	CbGpPWpGaD
Vincristine—TUBB2A—Transmembrane transport of small molecules—CP—psoriasis	6.44e-05	0.00271	CbGpPWpGaD
Vincristine—Diarrhoea—Prednisone—psoriasis	6.41e-05	0.000344	CcSEcCtD
Vincristine—Gastrointestinal pain—Methotrexate—psoriasis	6.4e-05	0.000344	CcSEcCtD
Vincristine—Nausea—Dexamethasone—psoriasis	6.39e-05	0.000343	CcSEcCtD
Vincristine—Nausea—Betamethasone—psoriasis	6.39e-05	0.000343	CcSEcCtD
Vincristine—TUBB3—Transmembrane transport of small molecules—CARM1—psoriasis	6.34e-05	0.00267	CbGpPWpGaD
Vincristine—TUBB1—Transmembrane transport of small molecules—CP—psoriasis	6.29e-05	0.00265	CbGpPWpGaD
Vincristine—NR0B1—Gene Expression—CARM1—psoriasis	6.25e-05	0.00263	CbGpPWpGaD
Vincristine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.25e-05	0.00263	CbGpPWpGaD
Vincristine—Dizziness—Prednisone—psoriasis	6.19e-05	0.000333	CcSEcCtD
Vincristine—Abdominal pain—Methotrexate—psoriasis	6.19e-05	0.000332	CcSEcCtD
Vincristine—Body temperature increased—Methotrexate—psoriasis	6.19e-05	0.000332	CcSEcCtD
Vincristine—TUBB2A—Transmembrane transport of small molecules—CARM1—psoriasis	6.14e-05	0.00258	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—IL12B—psoriasis	6.07e-05	0.00256	CbGpPWpGaD
Vincristine—TUBB4A—Metabolism of proteins—REN—psoriasis	6.04e-05	0.00254	CbGpPWpGaD
Vincristine—TUBB1—Transmembrane transport of small molecules—CARM1—psoriasis	6e-05	0.00253	CbGpPWpGaD
Vincristine—Vomiting—Prednisone—psoriasis	5.96e-05	0.00032	CcSEcCtD
Vincristine—ABCB1—Allograft Rejection—HLA-E—psoriasis	5.93e-05	0.00249	CbGpPWpGaD
Vincristine—Rash—Prednisone—psoriasis	5.91e-05	0.000317	CcSEcCtD
Vincristine—Dermatitis—Prednisone—psoriasis	5.9e-05	0.000317	CcSEcCtD
Vincristine—Headache—Prednisone—psoriasis	5.87e-05	0.000315	CcSEcCtD
Vincristine—Hypersensitivity—Methotrexate—psoriasis	5.77e-05	0.00031	CcSEcCtD
Vincristine—TUBB4A—Transmembrane transport of small molecules—CP—psoriasis	5.65e-05	0.00238	CbGpPWpGaD
Vincristine—Asthenia—Methotrexate—psoriasis	5.62e-05	0.000302	CcSEcCtD
Vincristine—Nausea—Prednisone—psoriasis	5.56e-05	0.000299	CcSEcCtD
Vincristine—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	5.54e-05	0.00233	CbGpPWpGaD
Vincristine—TUBB4B—Metabolism of proteins—REN—psoriasis	5.52e-05	0.00232	CbGpPWpGaD
Vincristine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.52e-05	0.00232	CbGpPWpGaD
Vincristine—NR0B1—Generic Transcription Pathway—PPARG—psoriasis	5.4e-05	0.00227	CbGpPWpGaD
Vincristine—TUBB4A—Transmembrane transport of small molecules—CARM1—psoriasis	5.39e-05	0.00227	CbGpPWpGaD
Vincristine—Diarrhoea—Methotrexate—psoriasis	5.36e-05	0.000288	CcSEcCtD
Vincristine—TUBA4A—Metabolism of proteins—ACE—psoriasis	5.35e-05	0.00225	CbGpPWpGaD
Vincristine—Dizziness—Methotrexate—psoriasis	5.18e-05	0.000278	CcSEcCtD
Vincristine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.18e-05	0.00218	CbGpPWpGaD
Vincristine—TUBB4B—Transmembrane transport of small molecules—CP—psoriasis	5.17e-05	0.00217	CbGpPWpGaD
Vincristine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.11e-05	0.00215	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—CCL20—psoriasis	5.08e-05	0.00214	CbGpPWpGaD
Vincristine—Vomiting—Methotrexate—psoriasis	4.98e-05	0.000267	CcSEcCtD
Vincristine—TUBA4A—Cell Cycle, Mitotic—PCNA—psoriasis	4.94e-05	0.00208	CbGpPWpGaD
Vincristine—Rash—Methotrexate—psoriasis	4.94e-05	0.000265	CcSEcCtD
Vincristine—SLC22A3—Metabolism—NDUFA5—psoriasis	4.93e-05	0.00208	CbGpPWpGaD
Vincristine—Dermatitis—Methotrexate—psoriasis	4.93e-05	0.000265	CcSEcCtD
Vincristine—TUBB4B—Transmembrane transport of small molecules—CARM1—psoriasis	4.93e-05	0.00207	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.91e-05	0.00206	CbGpPWpGaD
Vincristine—Headache—Methotrexate—psoriasis	4.9e-05	0.000263	CcSEcCtD
Vincristine—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	4.82e-05	0.00203	CbGpPWpGaD
Vincristine—ABCB11—Metabolism—NDUFA5—psoriasis	4.73e-05	0.00199	CbGpPWpGaD
Vincristine—Nausea—Methotrexate—psoriasis	4.65e-05	0.00025	CcSEcCtD
Vincristine—TUBB2B—Metabolism of proteins—ACE—psoriasis	4.59e-05	0.00193	CbGpPWpGaD
Vincristine—TUBB6—Metabolism of proteins—ACE—psoriasis	4.59e-05	0.00193	CbGpPWpGaD
Vincristine—SLC22A3—Transmembrane transport of small molecules—CP—psoriasis	4.58e-05	0.00193	CbGpPWpGaD
Vincristine—ABCC3—Metabolism—NDUFA5—psoriasis	4.53e-05	0.00191	CbGpPWpGaD
Vincristine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.47e-05	0.00188	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—IL10—psoriasis	4.44e-05	0.00187	CbGpPWpGaD
Vincristine—TUBB3—Metabolism of proteins—ACE—psoriasis	4.43e-05	0.00187	CbGpPWpGaD
Vincristine—TUBA4A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	4.42e-05	0.00186	CbGpPWpGaD
Vincristine—TUBA4A—Cell Cycle—PCNA—psoriasis	4.42e-05	0.00186	CbGpPWpGaD
Vincristine—ABCB11—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.41e-05	0.00186	CbGpPWpGaD
Vincristine—SLC22A3—Transmembrane transport of small molecules—CARM1—psoriasis	4.37e-05	0.00184	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—IL4—psoriasis	4.32e-05	0.00182	CbGpPWpGaD
Vincristine—TUBB2A—Metabolism of proteins—ACE—psoriasis	4.29e-05	0.00181	CbGpPWpGaD
Vincristine—ABCC3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.23e-05	0.00178	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.22e-05	0.00178	CbGpPWpGaD
Vincristine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.22e-05	0.00178	CbGpPWpGaD
Vincristine—ABCC3—Transmembrane transport of small molecules—CP—psoriasis	4.21e-05	0.00177	CbGpPWpGaD
Vincristine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.21e-05	0.00177	CbGpPWpGaD
Vincristine—TUBB—Cell Cycle, Mitotic—PCNA—psoriasis	4.2e-05	0.00177	CbGpPWpGaD
Vincristine—TUBB1—Metabolism of proteins—ACE—psoriasis	4.2e-05	0.00177	CbGpPWpGaD
Vincristine—SLC22A3—Metabolism—CYP2S1—psoriasis	4.19e-05	0.00176	CbGpPWpGaD
Vincristine—ABCB11—Metabolism—CYP2S1—psoriasis	4.02e-05	0.00169	CbGpPWpGaD
Vincristine—ABCC3—Transmembrane transport of small molecules—CARM1—psoriasis	4.02e-05	0.00169	CbGpPWpGaD
Vincristine—TUBA4A—Hemostasis—NOS2—psoriasis	3.94e-05	0.00166	CbGpPWpGaD
Vincristine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.93e-05	0.00165	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.91e-05	0.00165	CbGpPWpGaD
Vincristine—ABCC3—Metabolism—CYP2S1—psoriasis	3.85e-05	0.00162	CbGpPWpGaD
Vincristine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.85e-05	0.00162	CbGpPWpGaD
Vincristine—TUBB4A—Metabolism of proteins—ACE—psoriasis	3.77e-05	0.00159	CbGpPWpGaD
Vincristine—TUBB—Cell Cycle—PCNA—psoriasis	3.76e-05	0.00158	CbGpPWpGaD
Vincristine—NR0B1—Gene Expression—VDR—psoriasis	3.73e-05	0.00157	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.58e-05	0.0015	CbGpPWpGaD
Vincristine—ABCC1—Metabolism—NDUFA5—psoriasis	3.55e-05	0.00149	CbGpPWpGaD
Vincristine—TUBB4A—Cell Cycle, Mitotic—PCNA—psoriasis	3.48e-05	0.00147	CbGpPWpGaD
Vincristine—TUBB4B—Metabolism of proteins—ACE—psoriasis	3.45e-05	0.00145	CbGpPWpGaD
Vincristine—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	3.34e-05	0.00141	CbGpPWpGaD
Vincristine—TUBA4A—Metabolism of proteins—LEP—psoriasis	3.32e-05	0.0014	CbGpPWpGaD
Vincristine—ABCC1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.31e-05	0.00139	CbGpPWpGaD
Vincristine—ABCC1—Transmembrane transport of small molecules—CP—psoriasis	3.3e-05	0.00139	CbGpPWpGaD
Vincristine—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	3.19e-05	0.00134	CbGpPWpGaD
Vincristine—TUBB4B—Cell Cycle, Mitotic—PCNA—psoriasis	3.19e-05	0.00134	CbGpPWpGaD
Vincristine—ABCC1—Transmembrane transport of small molecules—CARM1—psoriasis	3.15e-05	0.00133	CbGpPWpGaD
Vincristine—ABCG2—Metabolism—NDUFA5—psoriasis	3.13e-05	0.00132	CbGpPWpGaD
Vincristine—TUBB4A—Cell Cycle—PCNA—psoriasis	3.11e-05	0.00131	CbGpPWpGaD
Vincristine—CYP3A7—Metabolism—NDUFA5—psoriasis	3.1e-05	0.0013	CbGpPWpGaD
Vincristine—ABCC1—Metabolism—CYP2S1—psoriasis	3.02e-05	0.00127	CbGpPWpGaD
Vincristine—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.9e-05	0.00122	CbGpPWpGaD
Vincristine—TUBB6—Metabolism of proteins—LEP—psoriasis	2.85e-05	0.0012	CbGpPWpGaD
Vincristine—TUBB2B—Metabolism of proteins—LEP—psoriasis	2.85e-05	0.0012	CbGpPWpGaD
Vincristine—TUBB4B—Cell Cycle—PCNA—psoriasis	2.85e-05	0.0012	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—SOCS1—psoriasis	2.8e-05	0.00118	CbGpPWpGaD
Vincristine—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.77e-05	0.00117	CbGpPWpGaD
Vincristine—TUBB3—Metabolism of proteins—LEP—psoriasis	2.75e-05	0.00116	CbGpPWpGaD
Vincristine—TUBB2A—Metabolism of proteins—LEP—psoriasis	2.67e-05	0.00112	CbGpPWpGaD
Vincristine—ABCG2—Metabolism—CYP2S1—psoriasis	2.66e-05	0.00112	CbGpPWpGaD
Vincristine—CYP3A7—Metabolism—CYP2S1—psoriasis	2.63e-05	0.00111	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—IFNG—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Vincristine—TUBB1—Metabolism of proteins—LEP—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Vincristine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.61e-05	0.0011	CbGpPWpGaD
Vincristine—NR0B1—Gene Expression—PPARG—psoriasis	2.6e-05	0.0011	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.43e-05	0.00102	CbGpPWpGaD
Vincristine—TUBB4A—Metabolism of proteins—LEP—psoriasis	2.34e-05	0.000985	CbGpPWpGaD
Vincristine—TUBA4A—Hemostasis—VEGFA—psoriasis	2.28e-05	0.000959	CbGpPWpGaD
Vincristine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.28e-05	0.000958	CbGpPWpGaD
Vincristine—CYP3A5—Metabolism—NDUFA5—psoriasis	2.24e-05	0.000942	CbGpPWpGaD
Vincristine—TUBA4A—Metabolism of proteins—CXCL8—psoriasis	2.21e-05	0.000929	CbGpPWpGaD
Vincristine—TUBB4B—Metabolism of proteins—LEP—psoriasis	2.14e-05	0.000901	CbGpPWpGaD
Vincristine—ABCB11—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.11e-05	0.000887	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—LEP—psoriasis	2.07e-05	0.000869	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—APOE—psoriasis	2.07e-05	0.000869	CbGpPWpGaD
Vincristine—SLC22A3—Metabolism—CARM1—psoriasis	2.05e-05	0.000862	CbGpPWpGaD
Vincristine—ABCC3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.02e-05	0.00085	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2e-05	0.000842	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.97e-05	0.00083	CbGpPWpGaD
Vincristine—ABCB11—Metabolism—CARM1—psoriasis	1.96e-05	0.000826	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—NFKBIA—psoriasis	1.93e-05	0.00081	CbGpPWpGaD
Vincristine—CYP3A5—Metabolism—CYP2S1—psoriasis	1.9e-05	0.000801	CbGpPWpGaD
Vincristine—TUBB6—Metabolism of proteins—CXCL8—psoriasis	1.89e-05	0.000797	CbGpPWpGaD
Vincristine—TUBB2B—Metabolism of proteins—CXCL8—psoriasis	1.89e-05	0.000797	CbGpPWpGaD
Vincristine—ABCC3—Metabolism—CARM1—psoriasis	1.88e-05	0.000792	CbGpPWpGaD
Vincristine—ABCB11—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.84e-05	0.000772	CbGpPWpGaD
Vincristine—TUBB3—Metabolism of proteins—CXCL8—psoriasis	1.83e-05	0.00077	CbGpPWpGaD
Vincristine—TUBB2A—Metabolism of proteins—CXCL8—psoriasis	1.77e-05	0.000746	CbGpPWpGaD
Vincristine—ABCC3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.76e-05	0.00074	CbGpPWpGaD
Vincristine—TUBB1—Metabolism of proteins—CXCL8—psoriasis	1.73e-05	0.000729	CbGpPWpGaD
Vincristine—TUBA4A—Hemostasis—TP53—psoriasis	1.72e-05	0.000725	CbGpPWpGaD
Vincristine—ABCB1—Allograft Rejection—TNF—psoriasis	1.69e-05	0.000711	CbGpPWpGaD
Vincristine—ABCB1—Metabolism—NDUFA5—psoriasis	1.69e-05	0.000711	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.68e-05	0.000707	CbGpPWpGaD
Vincristine—TUBA4A—Cell Cycle—TP53—psoriasis	1.63e-05	0.000684	CbGpPWpGaD
Vincristine—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.58e-05	0.000666	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—TYK2—psoriasis	1.58e-05	0.000664	CbGpPWpGaD
Vincristine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.57e-05	0.000661	CbGpPWpGaD
Vincristine—TUBB4A—Metabolism of proteins—CXCL8—psoriasis	1.56e-05	0.000655	CbGpPWpGaD
Vincristine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.5e-05	0.00063	CbGpPWpGaD
Vincristine—ABCC1—Metabolism—CARM1—psoriasis	1.48e-05	0.000621	CbGpPWpGaD
Vincristine—ABCB1—Metabolism—CYP2S1—psoriasis	1.44e-05	0.000605	CbGpPWpGaD
Vincristine—TUBB4B—Metabolism of proteins—CXCL8—psoriasis	1.42e-05	0.000599	CbGpPWpGaD
Vincristine—TUBB—Cell Cycle—TP53—psoriasis	1.38e-05	0.000582	CbGpPWpGaD
Vincristine—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.38e-05	0.00058	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—CXCL8—psoriasis	1.37e-05	0.000578	CbGpPWpGaD
Vincristine—ABCG2—Metabolism—CARM1—psoriasis	1.3e-05	0.000546	CbGpPWpGaD
Vincristine—CYP3A7—Metabolism—CARM1—psoriasis	1.29e-05	0.000541	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—JUN—psoriasis	1.28e-05	0.000537	CbGpPWpGaD
Vincristine—SLC22A3—Metabolism—CAT—psoriasis	1.26e-05	0.00053	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—NFKB1—psoriasis	1.23e-05	0.000517	CbGpPWpGaD
Vincristine—ABCB11—Metabolism—CAT—psoriasis	1.21e-05	0.000508	CbGpPWpGaD
Vincristine—ABCC3—Metabolism—CAT—psoriasis	1.16e-05	0.000487	CbGpPWpGaD
Vincristine—TUBB4A—Cell Cycle—TP53—psoriasis	1.15e-05	0.000482	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—VEGFA—psoriasis	1.12e-05	0.000469	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.11e-05	0.000469	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—STAT3—psoriasis	1.1e-05	0.000465	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.07e-05	0.000451	CbGpPWpGaD
Vincristine—TUBB4B—Cell Cycle—TP53—psoriasis	1.05e-05	0.000441	CbGpPWpGaD
Vincristine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.04e-05	0.000438	CbGpPWpGaD
Vincristine—SLC22A3—Metabolism—APOE—psoriasis	9.79e-06	0.000412	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.73e-06	0.00041	CbGpPWpGaD
Vincristine—ABCB11—Metabolism—APOE—psoriasis	9.38e-06	0.000395	CbGpPWpGaD
Vincristine—CYP3A5—Metabolism—CARM1—psoriasis	9.3e-06	0.000391	CbGpPWpGaD
Vincristine—ABCC1—Metabolism—CAT—psoriasis	9.07e-06	0.000382	CbGpPWpGaD
Vincristine—ABCC1—Disease—HLA-A—psoriasis	9.02e-06	0.000379	CbGpPWpGaD
Vincristine—ABCC3—Metabolism—APOE—psoriasis	9e-06	0.000379	CbGpPWpGaD
Vincristine—CYP3A4—Metabolism—CYP2S1—psoriasis	8.85e-06	0.000373	CbGpPWpGaD
Vincristine—SLC22A3—Metabolism—PPARG—psoriasis	8.53e-06	0.000359	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—TP53—psoriasis	8.43e-06	0.000355	CbGpPWpGaD
Vincristine—ABCC1—Disease—APOE—psoriasis	8.42e-06	0.000354	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.34e-06	0.000351	CbGpPWpGaD
Vincristine—ABCB11—Metabolism—PPARG—psoriasis	8.17e-06	0.000344	CbGpPWpGaD
Vincristine—ABCG2—Metabolism—CAT—psoriasis	7.98e-06	0.000336	CbGpPWpGaD
Vincristine—CYP3A7—Metabolism—CAT—psoriasis	7.91e-06	0.000333	CbGpPWpGaD
Vincristine—ABCC1—Disease—NOS2—psoriasis	7.84e-06	0.00033	CbGpPWpGaD
Vincristine—ABCC3—Metabolism—PPARG—psoriasis	7.84e-06	0.00033	CbGpPWpGaD
Vincristine—RALBP1—Signaling Pathways—IL6—psoriasis	7.71e-06	0.000325	CbGpPWpGaD
Vincristine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.35e-06	0.000309	CbGpPWpGaD
Vincristine—ABCC1—Metabolism—APOE—psoriasis	7.05e-06	0.000297	CbGpPWpGaD
Vincristine—ABCB1—Metabolism—CARM1—psoriasis	7.02e-06	0.000295	CbGpPWpGaD
Vincristine—ABCC1—Disease—TYK2—psoriasis	6.42e-06	0.00027	CbGpPWpGaD
Vincristine—ABCG2—Metabolism—APOE—psoriasis	6.2e-06	0.000261	CbGpPWpGaD
Vincristine—CYP3A7—Metabolism—APOE—psoriasis	6.15e-06	0.000259	CbGpPWpGaD
Vincristine—ABCC1—Metabolism—PPARG—psoriasis	6.14e-06	0.000258	CbGpPWpGaD
Vincristine—ABCC1—Disease—CD4—psoriasis	5.81e-06	0.000244	CbGpPWpGaD
Vincristine—CYP3A5—Metabolism—CAT—psoriasis	5.72e-06	0.000241	CbGpPWpGaD
Vincristine—ABCG2—Metabolism—PPARG—psoriasis	5.4e-06	0.000227	CbGpPWpGaD
Vincristine—CYP3A7—Metabolism—PPARG—psoriasis	5.36e-06	0.000225	CbGpPWpGaD
Vincristine—ABCC1—Disease—STAT3—psoriasis	4.5e-06	0.000189	CbGpPWpGaD
Vincristine—CYP3A5—Metabolism—APOE—psoriasis	4.44e-06	0.000187	CbGpPWpGaD
Vincristine—CYP3A4—Metabolism—CARM1—psoriasis	4.32e-06	0.000182	CbGpPWpGaD
Vincristine—ABCB1—Metabolism—CAT—psoriasis	4.32e-06	0.000182	CbGpPWpGaD
Vincristine—CYP3A5—Metabolism—PPARG—psoriasis	3.87e-06	0.000163	CbGpPWpGaD
Vincristine—ABCB1—Metabolism—APOE—psoriasis	3.35e-06	0.000141	CbGpPWpGaD
Vincristine—ABCC1—Disease—IL6—psoriasis	3.14e-06	0.000132	CbGpPWpGaD
Vincristine—ABCB1—Metabolism—PPARG—psoriasis	2.92e-06	0.000123	CbGpPWpGaD
Vincristine—CYP3A4—Metabolism—CAT—psoriasis	2.66e-06	0.000112	CbGpPWpGaD
Vincristine—CYP3A4—Metabolism—APOE—psoriasis	2.07e-06	8.69e-05	CbGpPWpGaD
Vincristine—CYP3A4—Metabolism—PPARG—psoriasis	1.8e-06	7.57e-05	CbGpPWpGaD
